A Vaccine For Pancreatic Cancer Continues To Show Promise
16:47 minutes
Pancreatic cancer is notoriously difficult to treat, and about 90% of diagnosed patients die from the disease. A team at Memorial Sloan Kettering has been working to improve those outcomes by developing a new mRNA vaccine for pancreatic cancer.
A few years ago, the team embarked on a small trial to test the vaccine’s safety. Sixteen patients with pancreatic cancer received it, and even though it was a small study, the results were promising: Half the participants had an immune response, and in those patients the cancer hadn’t relapsed after 18 months.
This week, the team released a new study in Nature following those same patients, and found six out of eight who responded to the vaccine in the first study did not have their cancer return more than three years later.
Joining host Flora Lichtman to talk about these results, and what they could mean for the future of cancer treatment, is study author and surgeon Dr. Vinod Balachandran, director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering, based in New York City.
Keep up with the week’s essential science news headlines, plus stories that offer extra joy and awe.
Dr. Vinod Balachandran is an associate attending surgeon and Director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering in New York, New York.
The transcript of this segment is being processed. It will be available early next week.
D Peterschmidt is a producer, host of the podcast Universe of Art, and composes music for Science Friday’s podcasts. Their D&D character is a clumsy bard named Chip Chap Chopman.
Flora Lichtman is a host of Science Friday. In a previous life, she lived on a research ship where apertivi were served on the top deck, hoisted there via pulley by the ship’s chef.